Final results of the RHAPSODY trial: a multi-center, phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein C, in combination with tissue plasminogen activator, mechanical thrombectomy or both in moderate to severe acute ischemic stroke. (vol 85, pg 125, 2019)

被引：0
|
作者：
不详
机构：
来源：
ANNALS OF NEUROLOGY | 2024年 / 95卷 / 02期
关键词：
D O I：
10.1002/ana.26841
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：417 / 417
页数：1
相关论文
共 1 条
  • [1] Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke
    Lyden, Patrick
    Pryor, Kent E.
    Coffey, Christopher S.
    Cudkowicz, Merit
    Conwit, Robin
    Jadhav, Ashutosh
    Sawyer, Robert N., Jr.
    Claassen, Jan
    Adeoye, Opeolu
    Song, Shlee
    Hannon, Peter
    Rost, Natalia S.
    Hinduja, Archana
    Torbey, Michel
    Lee, Jin-Moo
    Benesch, Curtis
    Rippee, Michael
    Rymer, Marilyn
    Froehler, Michael T.
    Clarke Haley, E.
    Johnson, Mark
    Yankey, Jon
    Magee, Kim
    Qidwai, Julie
    Levy, Howard
    Mark Haacke, E.
    Fawaz, Miller
    Davis, Thomas P.
    Toga, Arthur W.
    Griffin, John H.
    Zlokovic, Berislav V.
    Pryor, Kent
    Zlokovic, Berslav
    Fornal, Kathleen
    Conwit, Robin
    Coull, Bruce
    Adams, Harold
    Bushnell, Cheryl
    Leira, Enrique
    Tirschwell, David
    Sansing, Lauren
    Kasner, Scott
    Savitz, Sean
    Meschia, James
    Cloyd, James
    Gurney, James
    Lynch, David
    Martin, Renee
    Jadhav, Ashutosh
    Ducruet, Andrew
    ANNALS OF NEUROLOGY, 2019, 85 (01) : 125 - 136
1